These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11799636)

  • 1. The case for lipid control.
    Lipold AG
    Bus Health; 2001 Dec; 19(12 Suppl A):12-5. PubMed ID: 11799636
    [No Abstract]   [Full Text] [Related]  

  • 2. Measure for measure--sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy.
    Rosenson RS
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):72-3. PubMed ID: 17237831
    [No Abstract]   [Full Text] [Related]  

  • 3. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract]   [Full Text] [Related]  

  • 4. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do we need a fasting lipid profile to assess cardiovascular risk?
    Grunberger G
    J Diabetes; 2011 Sep; 3(3):172-3. PubMed ID: 21668658
    [No Abstract]   [Full Text] [Related]  

  • 6. The editor's roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular risk.
    Sulkes D; Brown BG; Krauss RM; Segrest JP; Sniderman AD; Roberts WC
    Am J Cardiol; 2008 Mar; 101(6):828-42. PubMed ID: 18328849
    [No Abstract]   [Full Text] [Related]  

  • 7. Opinion: Tight blood glucose control and cardiovascular disease in the elderly diabetic? Let the randomized controlled trials speak for themselves.
    Sherman FT
    Geriatrics; 2008 Aug; 63(8):8-10. PubMed ID: 18672951
    [No Abstract]   [Full Text] [Related]  

  • 8. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
    Cannon CP
    Am J Cardiol; 2008 Dec; 102(12A):5L-9L. PubMed ID: 19084083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into understanding cardiometabolic risk. Introduction.
    Fonarow GC; Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S1-2. PubMed ID: 17934389
    [No Abstract]   [Full Text] [Related]  

  • 11. Use it or lose it: exercise, diabetes and CVD.
    Gottlieb SH
    Diabetes Forecast; 2002 May; 55(5):39-41. PubMed ID: 14964157
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiologist's role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus.
    Gotto AM
    Am J Cardiol; 2007 Feb; 99(4A):3B-5B. PubMed ID: 17307053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating diabetes: cardiovascular benefits of antidiabetes drugs.
    Harmel AP
    Am J Manag Care; 2002 May; 8(8 Suppl):S219-28; quiz S229-32. PubMed ID: 12022237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid screening and cardiovascular health in childhood.
    Daniels SR; Greer FR;
    Pediatrics; 2008 Jul; 122(1):198-208. PubMed ID: 18596007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moderate exercise reduces the risk of heart disease and death in men with type 2 diabetes.
    Rollins G
    Rep Med Guidel Outcomes Res; 2003 Jun; 14(11):10, 12. PubMed ID: 12877117
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum.
    Karasik A
    Ann Med; 2005; 37(4):250-8. PubMed ID: 16019723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol goals established for patients with diabetes and metabolic syndrome.
    Haffner SM
    Am J Manag Care; 2002 Jan; Suppl():6-7. PubMed ID: 11833456
    [No Abstract]   [Full Text] [Related]  

  • 18. "K-ration". Diabetes and cardiovascular risk.
    Gottlieb SH
    Diabetes Forecast; 2002 Feb; 55(2):44-6. PubMed ID: 14959668
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors.
    Daousi C; Casson IF; Gill GV; MacFarlane IA; Wilding JP; Pinkney JH
    Postgrad Med J; 2006 Apr; 82(966):280-4. PubMed ID: 16597817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk in the spectrum of type 2 diabetes mellitus.
    Ahmed I; Goldstein BJ
    Mt Sinai J Med; 2006 Sep; 73(5):759-68. PubMed ID: 17008936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.